Montrouge, France, March 8, 2024
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the "Company"), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission ("SEC") and its Universal Registration Document ("URD") with the French market authority, "Autorité des Marchés Financiers" ("AMF").
These documents can be accessed on the Investors section of the Company's website at www.dbv-technologies.com (http://www.dbv-technologies.com). In addition, the URD is available on the AMF's website at www.amf-france.org (http://www.amf-france.org) and the Form 10-K is available on the SEC's website at www.sec.gov (http://www.sec.gov).
Printed copies of both documents are available, free of charge, at the Company's
headquarters and registered office located at 177-181 avenue Pierre Brossolette 92120 Montrouge, France.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin(TM), to address food allergies,
which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis.
Millions of people live with food allergies including young children. Through epicutaneous immunotherapy (EPIT(TM)), the Viaskin platform is designed to
introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Montrouge, France, with North American operations in Basking Ridge, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
For more information, please visit www.dbvtechnologies.com (https://url.avanan.click/v2/___http://www.dbvtechnologies.com___.YXAzOmRidi10ZW
Nobm9sb2dpZXM6YTpvOjViOGJmMDFkYTI0Y2Y1YTJjOGRmMmJhMWViZWZhOTA0OjY6MTQ0YjpiYWQxOD
NhM2FmYjk4ZDUyMGJmNDA3NDU2OWY4MjExM2I0OWE3NTA4MTIwYjdhMDJiY2Q4M2JjNjU1ZTMzM2RhOn
A6Rg) and engage with us on X (formerly Twitter) (https://url.avanan.click/v2/___https://twitter.com/DBVTechnologies___.YXAzOmRid
i10ZWNobm9sb2dpZXM6YTpvOjViOGJmMDFkYTI0Y2Y1YTJjOGRmMmJhMWViZWZhOTA0OjY6M2FkZjoyO
TZlMjFjNGE5NDJjYjU5N2Q4MWQwMzAxOTQ3N2UyOWU4ZWUxYzBkMWI0YzdlN2IxMjk5MmQ4ZmIwN2ZmZ
GEwOnA6Rg) and LinkedIn (https://url.avanan.click/v2/___https://www.linkedin.com/company/dbv-
technologies/___.YXAzOmRidi10ZWNobm9sb2dpZXM6YTpvOjViOGJmMDFkYTI0Y2Y1YTJjOGRmMmJ
hMWViZWZhOTA0OjY6ZWM5ODpiYmIxMDU3N2E3NGU0ZTQwOGZmZDMzOTNhYjkzMDM3OGY3ODRiZDI4MzV
iZDQ4NmNmOWNmZGJlMjdlMzUyZWQ4OnA6Rg).
Viaskin and EPIT are trademarks of DBV Technologies.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com (mailto:katie.matthews@dbv-technologies.com)
Media Contact
Aurora Krause
DBV Technologies
aurora.krause-ext@dbv-technologies.com (mailto:aurora.krause-ext@dbv- technologies.com)
Â